Temsirolimus and antimüllerian hormone protect fertility and the ovarian reserve against chemotherapy-induced damage in a murine model

Lara Houeis, Graziella van der Plancke, Luciana Cacciottola, Apolline Goudmaeker, Candice Kluyskens, Margherita Zipponi, Jean‐Paul Dehoux, Jacques Donnez, Marie‐Madeleine Dolmans
In: Fertility and Sterility · 2025 · vol. 125(1) , pp. 137–147 · doi:10.1016/j.fertnstert.2025.07.030 · PMID:40712967 · W4412701698
article OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-13 ⓘ

Temsirolimus and anti-Müllerian hormone were found to protect fertility and the ovarian reserve from chemotherapy-induced damage in a murine model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

The paper evaluated whether temsirolimus, anti-Müllerian hormone (AMH), or their combination can protect ovarian reserve and fertility outcomes after chemotherapy in a mouse model, using reproductive endpoints and ovarian assessments of follicle/ovarian status. The main finding was that treated animals showed preservation of fertility capacity and markers of ovarian reserve compared with chemotherapy-exposed controls. The study’s limitations include that results are based on an animal model with preclinical endpoints, which may not directly translate to humans. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

ObjectiveTo investigate the effects of temsirolimus (Tem) and recombinant antimüllerian hormone (AMH) on fertility and the ovarian reserve when associated with chemotherapy.DesignThirty-seven female mice were assigned to one of three treatment groups: control group; chemotherapy group; and gonadoprotection group. Five weeks after treatment, the mice underwent ovarian stimulation and were mated with males to evaluate residual fertility. Two days after mating, the animals were euthanized for embryo collection, and the ovaries were retrieved to assess the ovarian reserve and follicle damage.SubjectsThirty-seven Naval Medical Research Institute mice.ExposureThe control group (n = 10) was given a 100-μL injection of phosphate-buffered saline. The chemotherapy group (n = 13) received a single 100-μL injection of chemotherapy (120-mg/kg cyclophosphamide and 12-mg/kg busulfan). The gonadoprotection group (n = 14) was administered five injections of 5-mg/kg Tem over 1 week prior to chemotherapy, followed by a chemotherapy injection and then five injections of 5-μg recombinant AMH over the next 24 hours.Main outcome measuresEmbryo count, follicle count and morphology, and immunostaining for apoptosis (cleaved caspase-3), follicle activation (phospho-Akt), and proliferation (Ki67).ResultsThe control group showed the highest mean number of retrieved embryos (41.40 ± 14.74), closely followed by the gonadoprotection group (36.27 ± 17.22), whereas the chemotherapy group exhibited a significant reduction (20.63 ± 12.12) compared to both groups. Regarding the ovarian reserve, the control group showed the highest total follicle count (897.4 ± 392.8), with no difference compared to the gonadoprotection group (714.4 ± 283.9); however, there was a significant decline in the chemotherapy group (320.7 ± 145.5) compared with those in both groups. In terms of follicle apoptosis and activation, no significant difference was observed between groups. Follicle proliferation rates were significantly higher in the chemotherapy group (59.38% ± 14.67%) than in the control group (20.72% ± 10.52%); but gonadoprotective treatment did curtail follicle proliferation (42.23% ± 18.37%) compared with the chemotherapy group.ConclusionOur findings suggest that Tem and AMH show promise as gonadoprotective agents, potentially protecting the ovarian reserve against chemotherapy and thereby preserving fertility. This could offer patients who cannot benefit from currently available techniques brand new fertility preservation options.
Full text 1,090 characters · extracted from oa-html · click to expand
Temsirolimus and anti-Müllerian hormone protect fertility and the ovarian reserve against chemotherapy-induced damage in a murine model (2026) Fertility and Sterility — Vol. 125, n° 1, p. 137-147 (2025) (2026) Fertility and Sterility — Vol. 125, n° 1, p. 137-147 (2025) Open Access - Adobe PDF - 21.35 MB - Authors - Author Houeis, Lara UCLouvain - Author van der plancke, Graziella UCLouvain - Author Cacciottola, Luciana UCLouvain - Author Goudmaeker, Apolline UCLouvain - Author Kluyskens, Candice UCLouvain - Author Zipponi, Margherita UCLouvain - Author Dehoux, Jean-Paul UCLouvain - Author Donnez, Jacques UCLouvain - Author - et. al. - Affiliations - APA - Chicago - FWB Houeis, L., van der plancke, G., Cacciottola, L., Goudmaeker, A., Kluyskens, C., Zipponi, M., Dehoux, J.-P., Donnez, J., Dolmans, M.-M., & et al. (2026). Temsirolimus and anti-Müllerian hormone protect fertility and the ovarian reserve against chemotherapy-induced damage in a murine model. Fertility and Sterility, 125(1), 137-147. https://doi.org/10.1016/j.fertnstert.2025.07.030 (Original work published 2025)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (48)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK